Brokerages Set FocalTherics (NASDAQ:FOCL) Target Price at $7.75

Shares of FocalTherics (NASDAQ:FOCL) have received a consensus rating of “Hold” from the five brokerages that are presently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation, one has given a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $7.75.

Several analysts have issued reports on FOCL shares. Wall Street Zen lowered FocalTherics from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price target on shares of FocalTherics in a research report on Tuesday, August 25th. Piper Sandler reiterated a “neutral” rating and set a $4.00 price target on shares of FocalTherics in a research note on Friday, August 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of FocalTherics in a report on Monday, August 17th. Finally, Mizuho set a $15.00 price objective on FocalTherics and gave the company an “outperform” rating in a research note on Friday, July 17th.

Insider Transactions at FocalTherics

In other FocalTherics news, Director David R. Horn acquired 10,000 shares of the business’s stock in a transaction that occurred on Friday, August 14th. The stock was bought at an average cost of $4.75 per share, with a total value of $47,500.00. Following the acquisition, the director owned 10,000 shares in the company, valued at approximately $47,500. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Fran Schulz acquired 10,000 shares of FocalTherics stock in a transaction that occurred on Friday, August 14th. The stock was acquired at an average price of $4.75 per share, with a total value of $47,500.00. Following the completion of the purchase, the director directly owned 15,100 shares in the company, valued at $71,725. This represents a 196.08% increase in their position. The SEC filing for this purchase provides additional information. Over the last three months, insiders have bought 116,000 shares of company stock valued at $551,000. 10.10% of the stock is currently owned by insiders.

Institutional Investors Weigh In On FocalTherics

Institutional investors have recently made changes to their positions in the stock. Flax Pond Capital LLC purchased a new position in shares of FocalTherics in the fourth quarter valued at $2,623,000. Rock Springs Capital Management LP boosted its stake in FocalTherics by 7.1% in the 1st quarter. Rock Springs Capital Management LP now owns 1,378,000 shares of the company’s stock worth $5,126,000 after purchasing an additional 91,500 shares during the period. Lido Advisors LLC purchased a new position in FocalTherics during the 1st quarter valued at about $40,000. SmartHarvest Portfolios LLC bought a new stake in shares of FocalTherics during the first quarter valued at about $38,000. Finally, Leonteq Securities AG bought a new stake in shares of FocalTherics during the fourth quarter valued at about $313,000. Hedge funds and other institutional investors own 62.74% of the company’s stock.

FocalTherics Stock Up 0.2%

FocalTherics stock opened at $4.11 on Tuesday. FocalTherics has a twelve month low of $1.75 and a twelve month high of $6.40. The company’s 50 day moving average is $5.10. The company has a market cap of $154.24 million, a P/E ratio of -3.99 and a beta of -0.07. The company has a quick ratio of 1.38, a current ratio of 1.60 and a debt-to-equity ratio of 1.79.

FocalTherics (NASDAQ:FOCL) last posted its quarterly earnings results on Friday, August 14th. The company reported ($0.39) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.19). FocalTherics had a negative return on equity of 248.00% and a negative net margin of 56.26%.The company had revenue of $13.20 million during the quarter. Equities analysts expect that FocalTherics will post -0.82 EPS for the current fiscal year.

FocalTherics Company Profile

EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications.